Potent LNA oligonucleotides for the inhibition of HIF-1A expression

Patent metadata

Field	Value
Publication number	US-9938527-B2
Application number	US-201615243646-A
Country	US
Kind code	B2
Filing date	Aug 22, 2016
Priority date	Nov 9, 2004
Publication date	Apr 10, 2018
Grant date	Apr 10, 2018

Abstract

The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5′-( T x )G x G x c s a s a s g s c s a s t s c s c s T x G x T -3′ and 5′-( G x )T x T x a s c s t s g s c s c s t s t s c s T x T x A -3′, wherein capital letters designate a beta-D-oxy-LNA nucleotide analog, small letters designate a 2-deoxynucleotide, underline designates either a beta-D-oxy-LNA nucleotide analog or a 2-deoxynucleotide, subscript “s” designates a phosphorothioate link between neighboring nucleotides/LNA nucleotide analogs, and subscript “x” designates either a phosphorothioate link or a phosphorodiester link between neighboring nucleotides/LNA nucleotide analogs, and wherein the sequence is optionally extended by up to five 2-deoxynucleotide units. The LNA oligonucleotides are useful for modulating the expression of hypoxia-inducible factor-1a (HIF-1a), e.g. in the treatment of cancer diseases, inhibiting angiogenesis, inducing apoptosis, preventing cellular proliferation, or treating an angiogenic disease, e.g. diabetic retinopathy, macular degeneration (ARMD), psoriasis, rheumatoid arthritis and other inflammatory diseases.

First claim

The invention claimed is:

1. A method for treating liver cancer, the method comprising administering to a liver-cancer patient a composition comprising a therapeutically effective amount of the LNA oligonucleotide

(SEQ ID NO. 1)

5′-T s G s G s c s a s a s g s c s a s t s c s c s T s G s T s a-3′

wherein the capital letters designate a beta-D-oxy-LNA nucleotide analogue, lower case letters designate a 2-deoxynucleotide, and subscript “s” designates a phosphorothioate link between neighboring nucleotides/LNA nucleotide analogues.

2. The method of claim 1 , wherein the liver cancer is a hepatoma.

3. The method of claim 1 , wherein the composition is administered at a dosage from 0.01 μg to 1 g of LNA oligonucleotide per kg of body weight.

4. The method of claim 3 , wherein the composition is administered at a dosage from 0.1 mg to 100 mg of LNA oligonucleotide per kg of body weight.

5. The method of claim 4 , wherein the composition is administered at a dosage from 0.1 mg to 40 mg of LNA oligonucleotide per kg of body weight.

6. The method of claim 3 wherein the composition is administered at a dosage from 0.5 mg to 10 mg of LNA oligonucleotide per kg of body weight.

7. The method of claim 1 , wherein the composition is administered daily.

8. The method of claim 1 , wherein the composition is administered at a frequency of 1 to 3 times per week for a period of 1 to 4 weeks.

9. The method of claim 1 , wherein the composition is administered parenterally.

10. The method of claim 1 , wherein the composition is administered intravenously.

11. The method of claim 1 , wherein the composition is administered intraperitoneally.

12. The method of claim 1 , wherein the composition is administered by bolus injection into a target organ.

Assignees

• Roche Innovation Ct Copenhagen As

Inventors

• Westergaard Majken
• Thrue Charlotte Albaek
• Rasmussen Frank
• Hansen Henrik Frydenlund

Classifications

• A61K31/7088

  Compounds having three or more nucleosides or nucleotides · CPC title

• C12N15/111

  General methods applicable to biologically active non-coding nucleic acids · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61N5/10

  X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence) · CPC title

• C12N2320/30

  Special therapeutic applications · CPC title